Bcl-2 Inhibition to Overcome Resistance to Chemo- and Immunotherapy

According to the World Health Organization (WHO), cancer is a leading cause of death worldwide. The identification of novel targets for cancer treatment is an area of intense work that has led Bcl-2 over-expression to be proposed as one of the hallmarks of cancer and Bcl-2 inhibition as a promising...

Descripción completa

Detalles Bibliográficos
Autores principales: García-Aranda, Marilina, Pérez-Ruiz, Elisabet, Redondo, Maximino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6321604/
https://www.ncbi.nlm.nih.gov/pubmed/30544835
http://dx.doi.org/10.3390/ijms19123950
_version_ 1783385482013442048
author García-Aranda, Marilina
Pérez-Ruiz, Elisabet
Redondo, Maximino
author_facet García-Aranda, Marilina
Pérez-Ruiz, Elisabet
Redondo, Maximino
author_sort García-Aranda, Marilina
collection PubMed
description According to the World Health Organization (WHO), cancer is a leading cause of death worldwide. The identification of novel targets for cancer treatment is an area of intense work that has led Bcl-2 over-expression to be proposed as one of the hallmarks of cancer and Bcl-2 inhibition as a promising strategy for cancer treatment. In this review, we describe the different pathways related to programmed cell death, the role of Bcl-2 family members in apoptosis resistance to anti-cancer treatments, and the potential utility of Bcl-2 inhibitors to overcome resistance to chemo- and immunotherapy.
format Online
Article
Text
id pubmed-6321604
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-63216042019-01-07 Bcl-2 Inhibition to Overcome Resistance to Chemo- and Immunotherapy García-Aranda, Marilina Pérez-Ruiz, Elisabet Redondo, Maximino Int J Mol Sci Review According to the World Health Organization (WHO), cancer is a leading cause of death worldwide. The identification of novel targets for cancer treatment is an area of intense work that has led Bcl-2 over-expression to be proposed as one of the hallmarks of cancer and Bcl-2 inhibition as a promising strategy for cancer treatment. In this review, we describe the different pathways related to programmed cell death, the role of Bcl-2 family members in apoptosis resistance to anti-cancer treatments, and the potential utility of Bcl-2 inhibitors to overcome resistance to chemo- and immunotherapy. MDPI 2018-12-08 /pmc/articles/PMC6321604/ /pubmed/30544835 http://dx.doi.org/10.3390/ijms19123950 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
García-Aranda, Marilina
Pérez-Ruiz, Elisabet
Redondo, Maximino
Bcl-2 Inhibition to Overcome Resistance to Chemo- and Immunotherapy
title Bcl-2 Inhibition to Overcome Resistance to Chemo- and Immunotherapy
title_full Bcl-2 Inhibition to Overcome Resistance to Chemo- and Immunotherapy
title_fullStr Bcl-2 Inhibition to Overcome Resistance to Chemo- and Immunotherapy
title_full_unstemmed Bcl-2 Inhibition to Overcome Resistance to Chemo- and Immunotherapy
title_short Bcl-2 Inhibition to Overcome Resistance to Chemo- and Immunotherapy
title_sort bcl-2 inhibition to overcome resistance to chemo- and immunotherapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6321604/
https://www.ncbi.nlm.nih.gov/pubmed/30544835
http://dx.doi.org/10.3390/ijms19123950
work_keys_str_mv AT garciaarandamarilina bcl2inhibitiontoovercomeresistancetochemoandimmunotherapy
AT perezruizelisabet bcl2inhibitiontoovercomeresistancetochemoandimmunotherapy
AT redondomaximino bcl2inhibitiontoovercomeresistancetochemoandimmunotherapy

Ejemplares similares